90
Participants
Start Date
March 27, 2023
Primary Completion Date
December 1, 2025
Study Completion Date
June 1, 2026
Tezepelumab
"Tezepelumab is supplied as a sterile, single-use, preservation-free, clear, colourless to slightly yellow liquid for subcutaneous administration in accessorized pre-filled syringes (APFS).~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram."
placebo
"APFS containing analogous placebo identical in appearance:~Injections will be performed by study staff (doctors or nurses) during face-to-face study visits in participating centres.~Subcutaneous injections are performed in a different body-part following the suggested rotation diagram."
RECRUITING
CHU Dijon, Dijon
RECRUITING
CHU Grenoble Alpes La Tronche, Grenoble
RECRUITING
APHP Bicêtre, Le Kremlin-Bicêtre
WITHDRAWN
CHRU Lille, Lille
RECRUITING
Hôpital de la Croix Rousse, Lyon
RECRUITING
Hôpital Nord Marseille, Marseille
RECRUITING
CHU de Montpelier, Montpellier
RECRUITING
APHP Bichat, Paris
RECRUITING
Hôpital Foch, Paris
RECRUITING
Hôpital Haut-Lévêque, Pessac
RECRUITING
CHRU Strasbourg, Strasbourg
RECRUITING
CHU Toulouse, Toulouse
University Hospital, Montpellier
OTHER